Fibroblast growth factor receptors, developmental corruption and malignant disease
- PMID: 23880303
- DOI: 10.1093/carcin/bgt254
Fibroblast growth factor receptors, developmental corruption and malignant disease
Abstract
Fibroblast growth factors (FGF) are a family of ligands that bind to four different types of cell surface receptor entitled, FGFR1, FGFR2, FGFR3 and FGFR4. These receptors differ in their ligand binding affinity and tissue distribution. The prototypical receptor structure is that of an extracellular region comprising three immunoglobulin (Ig)-like domains, a hydrophobic transmembrane segment and a split intracellular tyrosine kinase domain. Alternative gene splicing affecting the extracellular third Ig loop also creates different receptor isoforms entitled FGFRIIIb and FGFRIIIc. Somatic fibroblast growth factor receptor (FGFR) mutations are implicated in different types of cancer and germline FGFR mutations occur in developmental syndromes particularly those in which craniosynostosis is a feature. The mutations found in both conditions are often identical. Many somatic FGFR mutations in cancer are gain-of-function mutations of established preclinical oncogenic potential. Gene amplification can also occur with 19-22% of squamous cell lung cancers for example having amplification of FGFR1. Ontologic comparators can be informative such as aberrant spermatogenesis being implicated in both spermatocytic seminomas and Apert syndrome. The former arises from somatic FGFR3 mutations and Apert syndrome arises from germline FGFR2 mutations. Finally, therapeutics directed at inhibiting the FGF/FGFR interaction are a promising subject for clinical trials.
Similar articles
-
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.Clin Cancer Res. 2013 Jul 1;19(13):3693-702. doi: 10.1158/1078-0432.CCR-13-0190. Epub 2013 May 8. Clin Cancer Res. 2013. PMID: 23658459 Clinical Trial.
-
Differential distribution of fibroblast growth factor receptors (FGFRs) on foveal cones: FGFR-4 is an early marker of cone photoreceptors.Mol Vis. 2004 Jan 8;10:1-14. Mol Vis. 2004. PMID: 14737068
-
Localisation and differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal and atherosclerotic human arteries.Cardiovasc Res. 1996 Sep;32(3):557-69. Cardiovasc Res. 1996. PMID: 8881516
-
FGF receptors: cancer biology and therapeutics.Med Res Rev. 2014 Mar;34(2):280-300. doi: 10.1002/med.21288. Epub 2013 May 21. Med Res Rev. 2014. PMID: 23696246 Review.
-
Heparan sulfate fibroblast growth factor receptor complex: structure-function relationships.Mol Reprod Dev. 1994 Sep;39(1):69-81; discusison 81-2. doi: 10.1002/mrd.1080390112. Mol Reprod Dev. 1994. PMID: 7999363 Review.
Cited by
-
Structure-based drug-development study against fibroblast growth factor receptor 2: molecular docking and Molecular dynamics simulation approaches.Sci Rep. 2024 Aug 21;14(1):19439. doi: 10.1038/s41598-024-69850-1. Sci Rep. 2024. PMID: 39169082 Free PMC article.
-
Review of published 467 achondroplasia patients: clinical and mutational spectrum.Orphanet J Rare Dis. 2024 Jan 27;19(1):29. doi: 10.1186/s13023-024-03031-1. Orphanet J Rare Dis. 2024. PMID: 38281003 Free PMC article. Review.
-
The NF-κB Pathway: a Focus on Inflammatory Responses in Spinal Cord Injury.Mol Neurobiol. 2023 Sep;60(9):5292-5308. doi: 10.1007/s12035-023-03411-x. Epub 2023 Jun 7. Mol Neurobiol. 2023. PMID: 37286724 Review.
-
The role of fibroblast growth factor 18 in cancers: functions and signaling pathways.Front Oncol. 2023 May 9;13:1124520. doi: 10.3389/fonc.2023.1124520. eCollection 2023. Front Oncol. 2023. PMID: 37228502 Free PMC article. Review.
-
FGF4 and FGF9 have synergistic effects on odontoblast differentiation.Med Mol Morphol. 2023 Sep;56(3):159-176. doi: 10.1007/s00795-023-00351-2. Epub 2023 Apr 3. Med Mol Morphol. 2023. PMID: 37012505
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous